244 related articles for article (PubMed ID: 12681268)
21. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
Sculpher M; Palmer S
Pharmacoeconomics; 2020 Mar; 38(3):247-257. PubMed ID: 31930460
[TBL] [Abstract][Full Text] [Related]
22. Reallocating resources: how should the National Institute for Health and Clinical Excellence guide disinvestment efforts in the National Health Service?
Pearson S; Littlejohns P
J Health Serv Res Policy; 2007 Jul; 12(3):160-5. PubMed ID: 17716419
[TBL] [Abstract][Full Text] [Related]
23. Does NICE apply the rule of rescue in its approach to highly specialised technologies?
Charlton V
J Med Ethics; 2022 Feb; 48(2):118-125. PubMed ID: 33685978
[TBL] [Abstract][Full Text] [Related]
24. At the center of health care policy making: the use of health technology assessment at NICE.
Stevens AJ; Longson C
Med Decis Making; 2013 Apr; 33(3):320-4. PubMed ID: 23519880
[TBL] [Abstract][Full Text] [Related]
25. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
[TBL] [Abstract][Full Text] [Related]
26. National Institute for Health and Clinical Excellence: the Medical Technologies Evaluation Programme.
J Med Eng Technol; 2011 Jul; 35(5):283-4. PubMed ID: 21635177
[TBL] [Abstract][Full Text] [Related]
27. Evidence-informed evidence-making.
Chalkidou K; Walley T; Culyer A; Littlejohns P; Hoy A
J Health Serv Res Policy; 2008 Jul; 13(3):167-73. PubMed ID: 18573766
[TBL] [Abstract][Full Text] [Related]
28. ABPI call for NICE guidance to be made mandatory.
Tiner R
Lancet Oncol; 2003 Apr; 4(4):203-4. PubMed ID: 12681260
[No Abstract] [Full Text] [Related]
29. Effects of the National Institute for Health and Clinical Excellence's technology appraisals on prescribing and net ingredient costs of drugs in the National Health Service in England.
Dietrich ES
Int J Technol Assess Health Care; 2009 Jul; 25(3):262-71. PubMed ID: 19619344
[TBL] [Abstract][Full Text] [Related]
30. NICE and LICE: lessons from a health district. National Institute for Clinical Excellence. Local institutes of clinical excellence.
Madhok R; Taylor A; Soltani H; Ireland K
J Public Health Med; 2002 Mar; 24(1):2-5. PubMed ID: 11939377
[TBL] [Abstract][Full Text] [Related]
31. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.
Kaltenthaler E; Boland A; Carroll C; Dickson R; Fitzgerald P; Papaioannou D
Health Technol Assess; 2011 May; 15(22):1-82, iii-iv. PubMed ID: 21561569
[TBL] [Abstract][Full Text] [Related]
32. Quality, innovation, and value for money: NICE and the British National Health Service.
Pearson SD; Rawlins MD
JAMA; 2005 Nov; 294(20):2618-22. PubMed ID: 16304076
[TBL] [Abstract][Full Text] [Related]
33. Decision making by NICE: examining the influences of evidence, process and context.
Cerri KH; Knapp M; Fernández JL
Health Econ Policy Law; 2014 Apr; 9(2):119-41. PubMed ID: 23688554
[TBL] [Abstract][Full Text] [Related]
34. Financial interests of patient organisations contributing to technology assessment at England's National Institute for Health and Care Excellence: policy review.
Mandeville KL; Barker R; Packham A; Sowerby C; Yarrow K; Patrick H
BMJ; 2019 Jan; 364():k5300. PubMed ID: 30651227
[TBL] [Abstract][Full Text] [Related]
35. When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.
Longworth L; Youn J; Bojke L; Palmer S; Griffin S; Spackman E; Claxton K
Pharmacoeconomics; 2013 Feb; 31(2):137-49. PubMed ID: 23329429
[TBL] [Abstract][Full Text] [Related]
36. Involving stakeholders in healthcare decisions--the experience of the National Institute for Health and Clinical Excellence (NICE) in England and Wales.
Culyer AJ
Healthc Q; 2005; 8(3):56-60. PubMed ID: 16078403
[TBL] [Abstract][Full Text] [Related]
37. Evidence and quality, practicalities and judgments: some experience from NICE.
Culyer A; Rawlins M
Healthc Q; 2012; 15 Spec No():66-9. PubMed ID: 24863122
[TBL] [Abstract][Full Text] [Related]
38. The normative grounds for NICE decision-making: a narrative cross-disciplinary review of empirical studies.
Charlton V
Health Econ Policy Law; 2022 Oct; 17(4):444-470. PubMed ID: 35293306
[TBL] [Abstract][Full Text] [Related]
39. A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?
Cowles E; Marsden G; Cole A; Devlin N
Appl Health Econ Health Policy; 2017 Aug; 15(4):469-477. PubMed ID: 28130691
[TBL] [Abstract][Full Text] [Related]
40. NICE system...shame about the side-effects.
McVie G
Lancet Oncol; 2003 Apr; 4(4):203. PubMed ID: 12681259
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
